- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.01. | Citizens reiterates Market Outperform rating on Rapport Therapeutics stock | 3 | Investing.com | ||
| 07.01. | Rapport Therapeutics, Inc.: Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline | 720 | GlobeNewswire (Europe) | U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second quarter... ► Artikel lesen | |
| 07.01. | Rapport Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.12.25 | Goldman Sachs bekräftigt Kaufempfehlung für Rapport Therapeutics nach Studienerfolg bei Epilepsie-Medikament | 11 | Investing.com Deutsch | ||
| 19.12.25 | Rapport Therapeutics stock holds Buy rating at Goldman Sachs on epilepsy drug efficacy | 3 | Investing.com | ||
| 09.12.25 | H.C. Wainwright raises Rapport Therapeutics stock price target to $40 on strong seizure drug data | 1 | Investing.com | ||
| RAPPORT THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 09.12.25 | Starke Studiendaten: H.C. Wainwright hebt Kursziel für Rapport Therapeutics auf 40 $ an | 10 | Investing.com Deutsch | ||
| 08.12.25 | Rapport Therapeutics: Citizens bestätigt "Market Outperform"-Rating nach neuen Studiendaten | 3 | Investing.com Deutsch | ||
| 05.12.25 | Rapport Therapeutics, Inc.: Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219's Clinical Response in Patients with Focal Onset Seizures | 1 | GlobeNewswire (USA) | ||
| 06.11.25 | Rapport Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11.25 | Rapport Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.09.25 | Truist Securities initiates Rapport Therapeutics stock with Buy rating | 9 | Investing.com | ||
| 11.09.25 | Rapport Therapeutics, Inc.: Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit | 1 | GlobeNewswire (USA) | ||
| 10.09.25 | Rapport Therapeutics prices $250M stock at $26 per share | 2 | Seeking Alpha | ||
| 10.09.25 | Rapport Therapeutics prices $250 million public offering at $26 per share | 2 | Investing.com | ||
| 10.09.25 | Rapport Therapeutics, Inc.: Rapport Announces Pricing of Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 08.09.25 | Rapport Therapeutics launches $250 million public stock offering | 16 | Investing.com | ||
| 08.09.25 | Rapport Therapeutics, Inc.: Rapport Announces Proposed Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 08.09.25 | Rapport Therapeutics: Stifel hebt Kursziel nach Studienerfolg deutlich auf 56 $ an | 4 | Investing.com Deutsch | ||
| 08.09.25 | Stifel raises Rapport Therapeutics stock price target to $56 on positive trial data | 2 | Investing.com |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOCRYST PHARMACEUTICALS | 5,392 | 0,00 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Report Fourth Quarter 2025 Financial Results on February 26 | ||
| MICROBOT MEDICAL | 1,475 | -1,80 % | Microbot Medical Inc. - 8-K, Current Report | ||
| IMMUNITYBIO | 5,118 | +0,08 % | ImmunityBio launches phase 2 trial for chemotherapy-free lymphoma therapy | ||
| VOYAGER THERAPEUTICS | 3,126 | +0,51 % | Voyager Therapeutics, Inc.: Voyager Reports Third Quarter 2025 Financial and Operating Results | - Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle discovery... ► Artikel lesen | |
| CAPRICOR | 19,000 | -9,31 % | Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data | FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review processCompany expects to submit updates to the BLA in February 2026 to support continued FDA review SAN DIEGO,... ► Artikel lesen | |
| ABEONA THERAPEUTICS | 4,280 | -1,38 % | Abeona Therapeutics Inc.: Abeona Therapeutics Announces Appointment of Mohamad Tabrizi as Chief Business Officer | CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 7,200 | -1,37 % | Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026 | ||
| VIR BIOTECHNOLOGY | 7,180 | +3,76 % | EQS-News: Norgine Pharmaceuticals Limited: Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung mit Vir Biotechnology | EQS-News: Norgine Pharmaceuticals Limited
/ Schlagwort(e): Produkteinführung/Vereinbarung
Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 65,00 | -7,14 % | Palvella Therapeutics: Clear Street bestätigt Kaufempfehlung im Vorfeld von Studiendaten | ||
| KALVISTA PHARMACEUTICALS | 12,200 | -3,17 % | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Compensation Committee of KalVista's Board of Directors granted six newly-hired employees inducement options to purchase an... ► Artikel lesen | |
| DBV TECHNOLOGIES | 3,520 | -3,43 % | DBV Technologies S.A.: Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026 | Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026
(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)
Market... ► Artikel lesen | |
| MARKER THERAPEUTICS | 1,260 | -9,35 % | Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates | APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma MT-601 demonstrated 66% objective response rate with 50% complete response in... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 5,500 | +0,92 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grants | ||
| ALIGOS THERAPEUTICS | 5,400 | -12,90 % | Aligos Therapeutics, Inc. - 8-K, Current Report | ||
| QUANTUM-SI | 1,060 | +13,72 % | Quantum-Si Inc - 8-K, Current Report |
Das Unternehmen RAPPORT THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +6,22 % bei einem Aktienkurs von 27,140 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RAPPORT THERAPEUTICS INC finden Sie auf Wallstreet Online.